Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice

Iron availability for erythropoiesis and its dysregulation in beta-thalassemia are incompletely understood. We previously demonstrated that exogenous apotransferrin leads to more effective erythropoiesis, decreasing erythroferrone (ERFE) and derepressing hepcidin in beta-thalassemic mice. Transferrin-bound iron binding to transferrin receptor 1 (TfR1) is essential for cellular iron delivery during erythropoiesis. We hypothesize that apotransferrin's effect is mediated via decreased TfR1 expression and evaluate TfR1 expression in beta-thalassemic mice in vivo and in vitro with and without added apotransferrin. Our findings demonstrate that beta-thalassemic erythroid precursors overexpress TfR1, an effect that can be reversed by the administration of exogenous apotransferrin. In vitro experiments demonstrate that apotransferrin inhibits TfR1 expression independent of erythropoietin-and iron-related signaling, decreases TfR1 partitioning to reticulocytes during enucleation, and enhances enucleation of defective beta-thalassemic erythroid precursors. These findings strongly suggest that overexpressed TfR1 mayplay a regulatory role contributing to iron overload and anemia in b-thalassemic mice. To evaluate further, we crossed TfR1 (+/-) mice, themselves exhibiting iron-restricted erythropoiesis with increased hepcidin, with b-thalassemic mice. Resultant double-heterozygote mice demonstrate long-term improvement in ineffective erythropoiesis, hepcidin derepression, and increased erythroid enucleation in relation to beta-thalassemic mice. Our data demonstrate for the first time that TfR1 (+/-) haploinsufficiency reverses iron overload specifically inb-thalassemic erythroid precursors. Taken together, decreasing TfR1 expression duringb-thalassemic erythropoiesis, either directly via induced haploinsufficiency or via exogenous apotransferrin, decreases ineffective erythropoiesis and provides an endogenous mechanism to upregulate hepcidin, leading to sustained ironrestricted erythropoiesis and preventing systemic iron overload in beta-thalassemic mice.